跳到正文
原文
STAT Pharma 医药频道· Allison DeAngelis·· 2026-10-08精选AI 评分71

罗氏与中国生物科技公司Defand Therapeutics达成分子胶药物研发合作

STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicines

AI 导读

罗氏与中国生物科技公司Defand Therapeutics签署合作,由后者负责发现与开发针对癌症和免疫驱动疾病的分子胶药物。交易潜在价值近10亿美元,涵盖首付款及研发与监管里程碑付款。

推荐理由

原文披露合作模式与潜在交易规模,读者可据此评估罗氏在分子胶药物领域的战略布局。

正文 · 原文

Roche is digging deeper into the biotech industry in China, striking a new partnership with a drug startup there. But rather than licensing the startup’s clinical-stage medicines, Roche is enlisting it to discover new ones, signaling a potential shift in global drug development. 

Chinese startup Defand Therapeutics said Thursday that it had signed a collaboration deal with Roche to develop molecular glue medicines. Under the deal, Defand will discover and develop multiple drugs for cancer and immune-driven diseases. The financial terms were not disclosed, but a source with knowledge of the agreement said it could be worth close to $1 billion between the upfront fee and payments Defand could get if it meets various preclinical, clinical, and regulatory goals. 

Molecular glue therapies are a buzzy new area of drug development, designed to create a sticky, more effective connection onto problematic proteins to destroy them. Development of these drugs has just begun to accelerate, thanks in large part to the data from Revolution Medicines, showing its molecular glue treatment Rasonque nearly doubled the survival rate of patients with pancreatic cancer. 

Continue to STAT+ to read the full story…

来源:STAT Pharma 医药频道 · statnews.com